Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MTDX 402
- Development stage
- Preclinical
- Lead developer
- Montdorex
- Modality
- Small Molecules
01
Overview
MTDX 402 is a proprietary small molecule pentamidine analog being developed by Montdorex for the treatment of gastrointestinal and liver diseases. As a non-cytotoxic di-amidine analog, it is designed to bind and neutralize lipopolysaccharides (LPS), thereby modulating LPS-driven inflammation and associated pathology. The drug is currently in the preclinical drug discovery phase and represents a precision medicine approach to treating inflammatory conditions where endotoxin-mediated signaling plays a central role. It is part of a broader pipeline of amidine-based compounds aimed at addressing inflammatory and oncological indications.
Beyond the preview
Go deeper on MTDX 402.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MTDX 402.